Sorin's Facil and Reply pacemakers approved in Japan
This article was originally published in Clinica
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the Facil and Reply pacemakers developed by Sorin. The dual- and single-chamber rate-responsive pacemakers are designed to prevent atrial fibrillation (AF). The Facil pacemaker is an 8cc device, and Reply offers the complete range of therapies in Facil with the addition of SafeR, an algorithm that allows the device to switch between atrial-based pacing and dual-chamber pacing modes. The Reply and Facil pacemakers will be distributed in Japan by Tokyo-based Japan Lifeline.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.